Literature DB >> 12194998

Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate.

W Pollock1, K Clarke, K Gallagher, J Hall, E Luckhurst, R McEvoy, J Melny, J Neil, A Nikoloutsopoulos, T Thompson, M Trevisin, J Savige.   

Abstract

BACKGROUND: The "International consensus statement on testing and reporting antineutrophil cytoplasmic antibodies (ANCA)" advocates screening by indirect immunofluorescence (IIF), but external quality assessment programmes often demonstrate different IIF patterns for a single serum. AIM: To determine whether the variation in IIF patterns can be attributed solely to errors in interpretation.
METHODS: This study compared the IIF patterns produced by four sera (two with cytoplasmic or C-ANCA; one with perinuclear or P-ANCA with myeloperoxidase (MPO) specificity; and one P-ANCA without MPO specificity) that were tested in 11 different laboratories. The sera were examined according to individual laboratory protocols at dilutions of 1/10 to 1/40 using P1 (n = 4), P2 (n = 2), P3 (n = 2), or in house (n=3) neutrophil preparations and conjugates from manufacturers C1 (n = 3), C2 (n = 1), C3 (n = 2), C4 (n = 1), C5 (n = 2), and C6 (n = 2). The IIF patterns were noted in each laboratory, the testing repeated, and the fluorescent patterns photographed and subsequently discussed at a meeting of the Australian ANCA study group.
RESULTS: All IIF patterns described in individual laboratories were confirmed on retesting and by the ANCA study group. Neutrophil substrates produced commercially or in house varied in their ability to demonstrate cytoplasmic granularity and interlobular accentuation, which distinguish between "C-ANCA" and "C-ANCA (atypical)". All commercial and in house neutrophil substrates demonstrated neutrophil nuclear extension of P-ANCA fluorescence, which correlates with MPO specificity. However, eight assays (eight of 43) from eight laboratories resulted in IIF patterns different from those usually seen. One of these produced a C-ANCA (atypical) rather than a C-ANCA pattern. The other seven resulted in at least some cytoplasmic fluorescence when the consensus pattern was P-ANCA with (n = 4) or without (n = 3) MPO specificity. These assays used three different commercial and one in house neutrophil substrate, and six different conjugates, with anti-IgG, anti-(Fab)'(2), anti-Ig (heavy and light chain), and anti-G, A, and M activity. Four of the seven assays tested on commercial substrates had used the manufacturer's conjugates.
CONCLUSIONS: This study indicates that the variation in IIF patterns seen with ANCA positive sera tested in different laboratories does not necessarily result from errors in the interpretation of patterns and cannot be attributed solely to the use of a particular neutrophil substrate or conjugate, or to the use of substrate from one manufacturer and conjugate from another.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12194998      PMCID: PMC1769745          DOI: 10.1136/jcp.55.9.680

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns.

Authors:  R C Wong; R A Silvestrini; J A Savige; D A Fulcher; E M Benson
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

3.  Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis.

Authors:  C O Savage; C G Winearls; S Jones; P D Marshall; C M Lockwood
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

4.  Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase.

Authors:  J L Niles; R T McCluskey; M F Ahmad; M A Arnaout
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

Review 5.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

Authors:  J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik
Journal:  Am J Clin Pathol       Date:  1999-04       Impact factor: 2.493

Review 6.  Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features.

Authors:  J Savige; D Davies; R J Falk; J C Jennette; A Wiik
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

7.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

8.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

9.  Some patients with anti-myeloperoxidase autoantibodies have a C-ANCA pattern.

Authors:  M Segelmark; B Baslund; J Wieslander
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

  9 in total
  4 in total

1.  Use of immunofluorescence and confocal laser scanning microscopy in identifying rare cases of anti-neutrophil cytoplasmic antibodies (ANCA) showing dual specificities to myeloperoxidase and proteinase3.

Authors:  S S Badakere; Vandana D Pradhan; A F Almeida; Aruna R Pawar
Journal:  J Fluoresc       Date:  2004-07       Impact factor: 2.217

2.  The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs.

Authors:  M Trevisin; P Neeson; J Savige
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

3.  PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).

Authors:  Laura M Stinton; Chelsea Bentow; Michael Mahler; Gary L Norman; Bertus Eksteen; Andrew L Mason; Gilaad G Kaplan; Bjorn Lindkvist; Gideon M Hirschfield; Piotr Milkiewicz; Angela Cheung; Harry L A Janssen; Marvin J Fritzler
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

4.  Laboratory Standard in the Diagnosis and Therapy Monitoring of Autoimmune Disease: Vasculitis.

Authors:  Branko Malenica
Journal:  EJIFCC       Date:  2006-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.